Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEVAC Fowl Pox Vaccine is a veterinary biological product developed by Middle East for Vaccines (MEVAC) for the active immunization of poultry against the fowl pox virus. Fowl pox is a viral infection characterized by cutaneous lesions on unfeathered skin or diphtheritic lesions in the upper digestive and respiratory tracts of chickens and turkeys. The vaccine is designed to stimulate a protective immune response, typically utilizing a live-attenuated strain of the virus. It is part of MEVAC's poultry vaccine portfolio, aimed at preventing the spread of the disease and reducing economic losses in commercial poultry operations. The vaccine is generally administered via the wing-web stab method to ensure effective localized and systemic immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MEVAC Fowl Pox Vaccine.